Tempest Therapeutics Secures Exclusive Option to License Senlang's CD7‑Targeted In Vivo CAR‑T Platform – Lead Bispecific BCMA/GPRC5D Candidate in Phase I for Relapsed/Refractory Multiple Myeloma
CompanyDeals

Tempest Therapeutics Secures Exclusive Option to License Senlang’s CD7‑Targeted In Vivo CAR‑T Platform – Lead Bispecific BCMA/GPRC5D Candidate in Phase I for Relapsed/Refractory Multiple Myeloma

Tempest Therapeutics, Inc. (NASDAQ: TPST) announced that it has entered into an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd., under which Tempest has acquired an exclusive option to…

ACROBiosystems and MediumBank Forge Strategic Partnership on AI‑Designed Proteins – Closed‑Loop Program Targets Thermostable bFGF and High‑Activity Cytokines for Cell Culture Media
CompanyDeals

ACROBiosystems and MediumBank Forge Strategic Partnership on AI‑Designed Proteins – Closed‑Loop Program Targets Thermostable bFGF and High‑Activity Cytokines for Cell Culture Media

NMPA Accepts Qilu Pharmaceutical's Marketing Application for Meropenem/Pralurbactam for Injection – First Independently Developed Novel β‑Lactamase Inhibitor Combination in China for cIAI
CompanyDrug

NMPA Accepts Qilu Pharmaceutical’s Marketing Application for Meropenem/Pralurbactam for Injection – First Independently Developed Novel β‑Lactamase Inhibitor Combination in China for cIAI

Escugen and Sovran Bio Sign Co‑Development Agreement for First‑in‑Class Pan‑Tumor Bispecific ADC – EZWi‑Fit Platform Powers Tumor‑Selective Payload Delivery
CompanyDeals

Escugen and Sovran Bio Sign Co‑Development Agreement for First‑in‑Class Pan‑Tumor Bispecific ADC – EZWi‑Fit Platform Powers Tumor‑Selective Payload Delivery

Hengrui's HRS-4139 Wins NMPA Clinical Trial Approval – Class 1 First‑in‑Target Candidate Targets Moderate‑to‑Severe Plaque Psoriasis
CompanyDrug

Hengrui’s HRS-4139 Wins NMPA Clinical Trial Approval – Class 1 First‑in‑Target Candidate Targets Moderate‑to‑Severe Plaque Psoriasis

- Advertisement -
Ad image
CompanyDrug

Otsuka Pharmaceutical Secures NMPA Approval for Voyxact (Sibeprenlimab) in IgA Nephropathy Based on Pivotal Phase III VISIONARY Data

CompanyDeals

Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases

CompanyDeals

Boji Medical Raises $66 Million Through Private Placement to Expand Integrated CRO and TCM Innovation Platform

CompanyDrug

Pfizer Secures FDA Approval for Marstacimab Expanded Indication in Hemophilia A and B Across Pediatric and Adult Populations

CompanyDrug

MSD and Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Study of Trodelvy-KEYTRUDA Combination in First-Line NSCLC

CompanyDeals

J&J to Acquire Firefly Bio for $1 Billion, Adding Proprietary DAC Platform Targeting KRAS-Driven Tumors

CompanyDeals

Nurix and Roche Forge $2.3 Billion Global Collaboration for BTK Degrader Bexobrutideg Across Oncology, Immunology and Neurology

Others

GSK to Acquire Nuvalent for $10.6 Billion, Adding Breakthrough Lung Cancer Therapies to Oncology Portfolio

CompanyDeals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

CompanyMedical Device

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

CompanyDrug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Novo Nordisk's CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy
CompanyDrug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Show More